COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Geminid meteor shower seen across China
- Sustainable agriculture in focus at Hainan forum
- Road accident in East China kills 4
- Health Bureau: Free Chinese medicine services for Tai Po fire victims
- Satellite launch marks a new milestone in UAE-China cooperation
- HK fire: 4,510 residents in shelters as support fund reaches HK$3.6b
